IOB / Institute of Oncology, Hospital Quirónsalud Barcelona

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC	Head and Neck Neoplasms, Mouth Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, laryngeal disorder, laryngeal neoplasm, mouth disorder, neoplasm, otorhinolaryngologic disease, respiratory system disorder, respiratory tract neoplasm, squamous cell carcinoma	Active, not recruiting	Phase 2 / Phase 3	2026-05-08		NCT06295731

Clinical trials